ICL Group Ltd (ICL)
Pre-market:
| Previous close | 4.7200 |
| Open | 4.7200 |
| Bid | 0.0000 x 1200 |
| Ask | 4.6800 x 1800 |
| Day's range | 4.5950 - 4.7200 |
| 52-week range | 4.3000 - 6.7300 |
| Volume | |
| Avg. volume | 783,753 |
| Market cap | 6.038B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 9.32 |
| EPS (TTM) | 0.5000 |
| Earnings date | N/A |
| Forward dividend & yield | 0.19 (4.10%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 5.30 |
Business WireICL Announces First Quarter 2024 Earnings Call
TEL AVIV, Israel, April 15, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced it plans to release first quarter 2024 results prior to the opening of the TASE market on Thursday, May 9, 2024.
Business WireICL Files 2023 Annual Report on Form 20-F
TEL AVIV, Israel, March 14, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (SEC). Included, for the third year in a row, are Task Force on Climate-related Financial Disclosures (TCFD), which provide information on what ICL is doing to mitigate the risks of climate change and reduce its carbon footprint.
Business WireICL Accelerating Biologicals Portfolio Growth in Brazil with Strategic Acquisition
TEL AVIV, Israel, February 28, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced it has acquired Nitro 1000, a manufacturer, developer and provider of biologicals in Brazil for approximately $30 million. This acquisition marks another meaningful step into the biologicals market, while expanding ICL’s product offerings and positioning the company for further expansions into new and adjacent end-markets.
